Default Category
-
Schon Klinik: Eating Disorder Care
Porter, Michael E.; Stanton, Emma; Hohman, Jessica A.; Stowell, CalebCase HBS-712475-EStrategyThe Schon Klinik is a private, for-profit German hospital group trying to establish itself as a premium health care provider in a competitive German market. The case details Schon Klinik's founding, its early focus on measurement and improvement, and the design and implementation of a system-wide structure for measuring and reporting actual health outcomes. The case details the care cycle for eating disorder patients and highlights the role outco...Starting at €8.20
-
Dr. Reddy's Laboratories (B)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M065-EStrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Dr. Reddy's Laboratories (A)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M064-EStrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Boehringer Ingelheim: Leading Innovation
J. Robert Mitchell; Ramasastry ChandrasekharCase IVEY-9B14M168-EEntrepreneurship, StrategyThe newly appointed director of Innovation Management & Strategy at Boehringer Ingelheim, a German-based multinational pharmaceutical company, is finding his way forward in his firm’s new, first-of-its-kind role, which is central to the company’s growth rejuvenation strategy. His job has a threefold mandate: to build internal networks, to establish internal structures and to leverage internal ideas. His biggest challenge, however, may be transfor...Starting at €8.20
-
Schon Klinik: Measuring Cost and Value
Kaplan, Robert S.; Witkowski, Mary L.; Hohman, Jessica A.Case HBS-112085-EFinanceThe case illustrates how a leading German hospital group has invested deeply in the measurement of patient-level outcomes and costs, the foundations of a health care value framework. The company launches a pilot project to use time-driven activity-based costing (TDABC) for measuring the cost of total knee replacements. The costing project complements an existing initiative for comprehensive outcomes measurement. The combination of accurate measur...Starting at €8.20
-
Volkswagen Strategy 2025: Shifting Gears in Disruptive Times
Andreas Schotter; Thomas Watson; Ramasastry ChandrasekharCase IVEY-9B19M047-EStrategyIn 2018, Volkswagen Group’s newly appointed chief executive officer renewed the company’s commitment to Strategy 2025, an ongoing plan intended to radically transform the German automaker. Volkswagen was being challenged by tectonic changes in the automotive industry, including the phasing out of the long-standing internal combustion engine, ongoing digitization, the entry of new competition from technology companies, the introduction of electric...Starting at €8.20
-
Dr. Reddy's Laboratories (A) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS64StrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Dr. Reddy's Laboratories (B) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS65StrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74